189 related articles for article (PubMed ID: 8113866)
1. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo.
Matsuda Y; Kawamoto K; Kiya K; Kurisu K; Sugiyama K; Uozumi T
J Neurosurg; 1994 Mar; 80(3):527-34. PubMed ID: 8113866
[TBL] [Abstract][Full Text] [Related]
2. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice.
Olson JJ; Beck DW; Schlechte JA; Loh PM
J Neurosurg; 1987 Apr; 66(4):584-7. PubMed ID: 3559725
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
Ragel BT; Gillespie DL; Kushnir V; Polevaya N; Kelly D; Jensen RL
Neurosurgery; 2006 Nov; 59(5):1109-20; discussion 1120-1. PubMed ID: 17143245
[TBL] [Abstract][Full Text] [Related]
4. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death.
Michna H; Schneider MR; Nishino Y; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):447-53. PubMed ID: 2626038
[TBL] [Abstract][Full Text] [Related]
5. Inverse correlation of cell proliferation and expression of progesterone receptors in tumor spheroids and monolayer cultures of human meningiomas.
Tonn JC; Ott MM; Bouterfa H; Kerkau S; Kapp M; Müller-Hermelink HK; Roosen K
Neurosurgery; 1997 Nov; 41(5):1152-9. PubMed ID: 9361071
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486).
Touat M; Lombardi G; Farina P; Kalamarides M; Sanson M
Acta Neurochir (Wien); 2014 Oct; 156(10):1831-5. PubMed ID: 25078073
[TBL] [Abstract][Full Text] [Related]
7. Mifepristone (RU 486) treatment of meningiomas.
Lamberts SW; Tanghe HL; Avezaat CJ; Braakman R; Wijngaarde R; Koper JW; de Jong H
J Neurol Neurosurg Psychiatry; 1992 Jun; 55(6):486-90. PubMed ID: 1619417
[TBL] [Abstract][Full Text] [Related]
8. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells.
Koper JW; Foekens JA; Braakman R; Lamberts SW
Cancer Res; 1990 May; 50(9):2604-7. PubMed ID: 2183929
[TBL] [Abstract][Full Text] [Related]
9. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.
Grunberg SM; Weiss MH; Spitz IM; Ahmadi J; Sadun A; Russell CA; Lucci L; Stevenson LL
J Neurosurg; 1991 Jun; 74(6):861-6. PubMed ID: 2033444
[TBL] [Abstract][Full Text] [Related]
10. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
11. Meningioma and hormonal influences.
Wahab M; Al-Azzawi F
Climacteric; 2003 Dec; 6(4):285-92. PubMed ID: 15006250
[TBL] [Abstract][Full Text] [Related]
12. Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma.
Altinoz MA; Ozpinar A; Elmaci I
Neurosurg Rev; 2019 Jun; 42(2):351-369. PubMed ID: 29453736
[TBL] [Abstract][Full Text] [Related]
13. Meningiomas, epidermal growth factor and progesterone.
Koper JW; Lamberts SW
Hum Reprod; 1994 Jun; 9 Suppl 1():190-4. PubMed ID: 7962464
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
[TBL] [Abstract][Full Text] [Related]
15. Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.
Gupta V; Samuleson CG; Su S; Chen TC
Neurosurg Focus; 2007; 23(4):E9. PubMed ID: 17961046
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
[TBL] [Abstract][Full Text] [Related]
17. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on growth of primary meningioma cells in monolayer tissue culture.
Waelti ER; Markwalder TM
Surg Neurol; 1989 Feb; 31(2):96-100. PubMed ID: 2522246
[TBL] [Abstract][Full Text] [Related]
18. The role of mifepristone in the management of meningiomas: A systematic review of literature.
Sharma R; Garg K; Katiyar V; Tandon V; Agarwal D; Singh M; Chandra SP; Suri A; Kale SS; Mahapatra AK
Neurol India; 2019; 67(3):698-705. PubMed ID: 31347538
[TBL] [Abstract][Full Text] [Related]
19. Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas. Correlation with clinical and morphological data.
Bouillot P; Pellissier JF; Devictor B; Graziani N; Bianco N; Grisoli F; Figarella-Branger D
J Neurosurg; 1994 Nov; 81(5):765-73. PubMed ID: 7523635
[TBL] [Abstract][Full Text] [Related]
20. Progesterone and glucocorticoid receptor activation in meningiomas.
Carroll RS; Zhang J; Dashner K; Black PM
Neurosurgery; 1995 Jul; 37(1):92-7. PubMed ID: 8587697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
